Period,symbol,NAV,sharesOutstanding,researchDevelopment,effectOfAccountingCharges,incomeBeforeTax,minorityInterest,netIncome,sellingGeneralAdministrative,grossProfit,ebit,operatingIncome,otherOperatingExpenses,interestExpense,extraordinaryItems,nonRecurring,otherItems,incomeTaxExpense,totalRevenue,totalOperatingExpenses,costOfRevenue,totalOtherIncomeExpenseNet,discontinuedOperations,netIncomeFromContinuingOps,netIncomeApplicableToCommonShares,intangibleAssets,totalLiab,totalStockholderEquity,otherCurrentLiab,totalAssets,commonStock,retainedEarnings,otherLiab,goodWill,treasuryStock,cash,totalCurrentLiabilities,otherStockholderEquity,propertyPlantEquipment,totalCurrentAssets,longTermInvestments,netReceivables,inventory,accountsPayable,changeToLiabilities,totalCashflowsFromInvestingActivities,netBorrowings,totalCashFromFinancingActivities,issuanceOfStock,changeInCash,effectOfExchangeRate,totalCashFromOperatingActivities,depreciation,otherCashflowsFromFinancingActivities,changeToNetincome,capitalExpenditures,changeToOperatingActivities,changeToInventory,changeToAccountReceivables,WC,language,region,quoteType,triggerable,quoteSourceName,currency,shortName,twoHundredDayAverageChangePercent,marketCap,priceToBook,sourceInterval,exchangeTimezoneName,exchangeTimezoneShortName,gmtOffSetMilliseconds,esgPopulated,tradeable,marketState,exchangeDataDelayedBy,priceHint,regularMarketPrice,regularMarketTime,regularMarketChange,regularMarketOpen,regularMarketDayHigh,regularMarketDayLow,regularMarketVolume,exchange,market,regularMarketChangePercent,regularMarketDayRange,regularMarketPreviousClose,bid,ask,bidSize,askSize,messageBoardId,fullExchangeName,longName,financialCurrency,averageDailyVolume3Month,averageDailyVolume10Day,fiftyTwoWeekLowChange,fiftyTwoWeekLowChangePercent,fiftyTwoWeekRange,fiftyTwoWeekHighChange,fiftyTwoWeekHighChangePercent,fiftyTwoWeekLow,fiftyTwoWeekHigh,epsTrailingTwelveMonths,bookValue,fiftyDayAverage,fiftyDayAverageChange,fiftyDayAverageChangePercent,twoHundredDayAverage,twoHundredDayAverageChange,Beta (5Y Monthly),52-Week Change 3,S&P500 52-Week Change 3,52 Week High 3,52 Week Low 3,50-Day Moving Average 3,200-Day Moving Average 3,Avg Vol (3 month) 3,Avg Vol (10 day) 3,Shares Outstanding 5,Implied Shares Outstanding 6,Float,% Held by Insiders 1,% Held by Institutions 1,Shares Short 4,Short Ratio 4,Short % of Float 4,Short % of Shares Outstanding 4,Shares Short (prior month ) 4,Forward Annual Dividend Rate 4,Forward Annual Dividend Yield 4,Trailing Annual Dividend Rate 3,Trailing Annual Dividend Yield 3,5 Year Average Dividend Yield 4,Payout Ratio 4,Dividend Date 3,Ex-Dividend Date 4,Last Split Factor 2,Last Split Date 3,Fiscal Year Ends,Most Recent Quarter (mrq),Profit Margin,Operating Margin (ttm),Return on Assets (ttm),Return on Equity (ttm),Revenue (ttm),Revenue Per Share (ttm),Quarterly Revenue Growth (yoy),Gross Profit (ttm),EBITDA,Net Income Avi to Common (ttm),Diluted EPS (ttm),Quarterly Earnings Growth (yoy),Total Cash (mrq),Total Cash Per Share (mrq),Total Debt (mrq),Total Debt/Equity (mrq),Current Ratio (mrq),Book Value Per Share (mrq),Operating Cash Flow (ttm),Levered Free Cash Flow (ttm),index,zip,sector,fullTimeEmployees,longBusinessSummary,city,phone,state,compensationAsOfEpochDate,country,website,maxAge,address1,fax,industry,address2
t0,IPDQF,18645000,1491680000,409500,,-5219000,,-5219000,5467000,1394500,-5981000,-5981000,704000,-15500,,,,0,1789500,7770500,395000,762000,,-5219000,-5219000,15000,6234000,25160000,4109000,31394000,258385000,-260499000,104000,6500000,27274000,19021000,5814000,27274000,796000,24010000,73000,3275000,776000,1374000,0.0,-487000.0,-27000.0,3942500.0,4005500.0,-321000.0,-459500.0,-3317000.0,421000.0,-36000.0,1481000.0,-20000.0,,,,18196000,en-US,US,EQUITY,False,Delayed Quote,USD,IMPEDIMED LIMITED,0.035684254,141112928,4.1130433,15,America/New_York,EDT,-14400000,False,False,PRE,0,4,0.0946,1630521239,-0.0029150024,0.0936,0.0946,0.0936,17500,PNK,us_market,-2.9892862,0.0936 - 0.0946,0.097515,0.0,0.0,0,0,finmb_29573707,Other OTC,ImpediMed Limited,AUD,20435,4385,0.0456,0.93061227,0.049 - 0.137,-0.042399995,-0.30948904,0.049,0.137,-0.016,0.023,0.08209429,0.01250571,0.1523335,0.09134058,0.0032594204,3.02,,,0.137,0.049,0.0821,0.0913,20.43k,4.38k,1.49B,,982.31M,7.75%,22.16%,,,,,,,,,,,0.00%,,,1027:1000,"Nov 16, 2014","Jun 29, 2020","Dec 30, 2020",-291.13%,-354.90%,-51.33%,-87.53%,6.48M,0.01,26.20%,4.06M,-22.68M,-18.87M,-0.0160,,19.02M,0.02,647k,2.57,4.13,0.02,-16.08M,-14.09M,Value,4008,Healthcare,69,"ImpediMed Limited, a medical software technology company, together with its subsidiaries, develops, manufactures, and sells bioimpedance spectroscopy (BIS) devices and software services in Australia, North America, and internationally. It offers SOZO, a noninvasive bioimpedance spectroscopy device for the detection of lymphedema and fluid status monitoring of heart failure patients; SFB7, a single-channel, tetrapolar BIS device to analyze body composition in healthy individuals; and ImpediVET, a single-channel, tetrapolar (BIS) device that measures fluid status and tissue composition for veterinary applications. The company sells its devices to hospitals and clinics. ImpediMed Limited was founded in 1999 and is headquartered in Pinkenba, Australia.",Pinkenba,61 7 3860 3700,QLD,1609372800,Australia,http://www.impedimed.com,86400,50 Parker Court,61 7 3260 1225,Medical Devices,Unit 1
t-1,IPDQF,18645000,1491680000,409500,,-5219000,,-5219000,5467000,1394500,-5981000,-5981000,704000,-15500,,,,0,1789500,7770500,395000,762000,,-5219000,-5219000,15000,6234000,25160000,4109000,31394000,258385000,-260499000,104000,6500000,27274000,19021000,5814000,27274000,796000,24010000,73000,3275000,776000,1374000,0.0,-487000.0,-27000.0,3942500.0,4005500.0,-321000.0,-459500.0,-3317000.0,421000.0,-36000.0,1481000.0,-20000.0,,,,18196000,en-US,US,EQUITY,False,Delayed Quote,USD,IMPEDIMED LIMITED,0.035684254,141112928,4.1130433,15,America/New_York,EDT,-14400000,False,False,PRE,0,4,0.0946,1630521239,-0.0029150024,0.0936,0.0946,0.0936,17500,PNK,us_market,-2.9892862,0.0936 - 0.0946,0.097515,0.0,0.0,0,0,finmb_29573707,Other OTC,ImpediMed Limited,AUD,20435,4385,0.0456,0.93061227,0.049 - 0.137,-0.042399995,-0.30948904,0.049,0.137,-0.016,0.023,0.08209429,0.01250571,0.1523335,0.09134058,0.0032594204,3.02,,,0.137,0.049,0.0821,0.0913,20.43k,4.38k,1.49B,,982.31M,7.75%,22.16%,,,,,,,,,,,0.00%,,,1027:1000,"Nov 16, 2014","Jun 29, 2020","Dec 30, 2020",-291.13%,-354.90%,-51.33%,-87.53%,6.48M,0.01,26.20%,4.06M,-22.68M,-18.87M,-0.0160,,19.02M,0.02,647k,2.57,4.13,0.02,-16.08M,-14.09M,Value,4008,Healthcare,69,"ImpediMed Limited, a medical software technology company, together with its subsidiaries, develops, manufactures, and sells bioimpedance spectroscopy (BIS) devices and software services in Australia, North America, and internationally. It offers SOZO, a noninvasive bioimpedance spectroscopy device for the detection of lymphedema and fluid status monitoring of heart failure patients; SFB7, a single-channel, tetrapolar BIS device to analyze body composition in healthy individuals; and ImpediVET, a single-channel, tetrapolar (BIS) device that measures fluid status and tissue composition for veterinary applications. The company sells its devices to hospitals and clinics. ImpediMed Limited was founded in 1999 and is headquartered in Pinkenba, Australia.",Pinkenba,61 7 3860 3700,QLD,1609372800,Australia,http://www.impedimed.com,86400,50 Parker Court,61 7 3260 1225,Medical Devices,Unit 1
t-2,IPDQF,20839000,1491680000,667000,,-4198500,,-4218000,5772000,980500,-5523000,-5523000,1064000,-18000,,,,19500,1452000,6975000,471500,1324500,,-4218000,-4218000,3886000,5703000,27361000,616000,33064000,250563000,-250061000,87000,2636000,26859000,19663000,5109000,26859000,1015000,25450000,77000,4515000,864000,1913000,-29000.0,-515000.0,-102500.0,8770500.0,9661000.0,3346000.0,-186500.0,-4723000.0,-91000.0,-788000.0,41500.0,-20000.0,-913000.0,128500.0,-128000.0,20341000,en-US,US,EQUITY,False,Delayed Quote,USD,IMPEDIMED LIMITED,0.035684254,141112928,4.1130433,15,America/New_York,EDT,-14400000,False,False,PRE,0,4,0.0946,1630521239,-0.0029150024,0.0936,0.0946,0.0936,17500,PNK,us_market,-2.9892862,0.0936 - 0.0946,0.097515,0.0,0.0,0,0,finmb_29573707,Other OTC,ImpediMed Limited,AUD,20435,4385,0.0456,0.93061227,0.049 - 0.137,-0.042399995,-0.30948904,0.049,0.137,-0.016,0.023,0.08209429,0.01250571,0.1523335,0.09134058,0.0032594204,3.02,,,0.137,0.049,0.0821,0.0913,20.43k,4.38k,1.49B,,982.31M,7.75%,22.16%,,,,,,,,,,,0.00%,,,1027:1000,"Nov 16, 2014","Jun 29, 2020","Dec 30, 2020",-291.13%,-354.90%,-51.33%,-87.53%,6.48M,0.01,26.20%,4.06M,-22.68M,-18.87M,-0.0160,,19.02M,0.02,647k,2.57,4.13,0.02,-16.08M,-14.09M,Value,4008,Healthcare,69,"ImpediMed Limited, a medical software technology company, together with its subsidiaries, develops, manufactures, and sells bioimpedance spectroscopy (BIS) devices and software services in Australia, North America, and internationally. It offers SOZO, a noninvasive bioimpedance spectroscopy device for the detection of lymphedema and fluid status monitoring of heart failure patients; SFB7, a single-channel, tetrapolar BIS device to analyze body composition in healthy individuals; and ImpediVET, a single-channel, tetrapolar (BIS) device that measures fluid status and tissue composition for veterinary applications. The company sells its devices to hospitals and clinics. ImpediMed Limited was founded in 1999 and is headquartered in Pinkenba, Australia.",Pinkenba,61 7 3860 3700,QLD,1609372800,Australia,http://www.impedimed.com,86400,50 Parker Court,61 7 3260 1225,Medical Devices,Unit 1
t-3,IPDQF,20839000,1491680000,667000,,-4198500,,-4218000,5772000,980500,-5523000,-5523000,1064000,-18000,,,,19500,1452000,6975000,471500,1324500,,-4218000,-4218000,3886000,5703000,27361000,616000,33064000,250563000,-250061000,87000,2636000,26859000,19663000,5109000,26859000,1015000,25450000,77000,4515000,864000,1913000,-29000.0,-515000.0,-102500.0,8770500.0,9661000.0,3346000.0,-186500.0,-4723000.0,-91000.0,-788000.0,41500.0,-20000.0,-913000.0,128500.0,-128000.0,20341000,en-US,US,EQUITY,False,Delayed Quote,USD,IMPEDIMED LIMITED,0.035684254,141112928,4.1130433,15,America/New_York,EDT,-14400000,False,False,PRE,0,4,0.0946,1630521239,-0.0029150024,0.0936,0.0946,0.0936,17500,PNK,us_market,-2.9892862,0.0936 - 0.0946,0.097515,0.0,0.0,0,0,finmb_29573707,Other OTC,ImpediMed Limited,AUD,20435,4385,0.0456,0.93061227,0.049 - 0.137,-0.042399995,-0.30948904,0.049,0.137,-0.016,0.023,0.08209429,0.01250571,0.1523335,0.09134058,0.0032594204,3.02,,,0.137,0.049,0.0821,0.0913,20.43k,4.38k,1.49B,,982.31M,7.75%,22.16%,,,,,,,,,,,0.00%,,,1027:1000,"Nov 16, 2014","Jun 29, 2020","Dec 30, 2020",-291.13%,-354.90%,-51.33%,-87.53%,6.48M,0.01,26.20%,4.06M,-22.68M,-18.87M,-0.0160,,19.02M,0.02,647k,2.57,4.13,0.02,-16.08M,-14.09M,Value,4008,Healthcare,69,"ImpediMed Limited, a medical software technology company, together with its subsidiaries, develops, manufactures, and sells bioimpedance spectroscopy (BIS) devices and software services in Australia, North America, and internationally. It offers SOZO, a noninvasive bioimpedance spectroscopy device for the detection of lymphedema and fluid status monitoring of heart failure patients; SFB7, a single-channel, tetrapolar BIS device to analyze body composition in healthy individuals; and ImpediVET, a single-channel, tetrapolar (BIS) device that measures fluid status and tissue composition for veterinary applications. The company sells its devices to hospitals and clinics. ImpediMed Limited was founded in 1999 and is headquartered in Pinkenba, Australia.",Pinkenba,61 7 3860 3700,QLD,1609372800,Australia,http://www.impedimed.com,86400,50 Parker Court,61 7 3260 1225,Medical Devices,Unit 1
